nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Hexylcaine—SCN10A—breast cancer	0.00338	0.546	CrCbGaD
Glycopyrrolate—Trospium—CYP2D6—breast cancer	0.00105	0.169	CrCbGaD
Glycopyrrolate—Oxybutynin—CYP2D6—breast cancer	0.000951	0.154	CrCbGaD
Glycopyrrolate—Oxybutynin—CYP3A4—breast cancer	0.000815	0.132	CrCbGaD
Glycopyrrolate—Confusional state—Docetaxel—breast cancer	0.000312	0.000394	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000311	0.000392	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Methotrexate—breast cancer	0.00031	0.000392	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Docetaxel—breast cancer	0.00031	0.000391	CcSEcCtD
Glycopyrrolate—Oedema—Docetaxel—breast cancer	0.00031	0.000391	CcSEcCtD
Glycopyrrolate—Epistaxis—Epirubicin—breast cancer	0.000309	0.00039	CcSEcCtD
Glycopyrrolate—Pruritus—Gemcitabine—breast cancer	0.000309	0.00039	CcSEcCtD
Glycopyrrolate—Nausea—Thiotepa—breast cancer	0.000308	0.000389	CcSEcCtD
Glycopyrrolate—Urethral disorder—Methotrexate—breast cancer	0.000308	0.000389	CcSEcCtD
Glycopyrrolate—Infection—Docetaxel—breast cancer	0.000308	0.000388	CcSEcCtD
Glycopyrrolate—Sinusitis—Epirubicin—breast cancer	0.000307	0.000388	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Doxorubicin—breast cancer	0.000307	0.000387	CcSEcCtD
Glycopyrrolate—Dry mouth—Capecitabine—breast cancer	0.000306	0.000386	CcSEcCtD
Glycopyrrolate—Pneumonia—Doxorubicin—breast cancer	0.000305	0.000385	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Docetaxel—breast cancer	0.000304	0.000383	CcSEcCtD
Glycopyrrolate—Pruritus—Fluorouracil—breast cancer	0.000304	0.000383	CcSEcCtD
Glycopyrrolate—Infestation—Doxorubicin—breast cancer	0.000303	0.000382	CcSEcCtD
Glycopyrrolate—Infestation NOS—Doxorubicin—breast cancer	0.000303	0.000382	CcSEcCtD
Glycopyrrolate—Drowsiness—Doxorubicin—breast cancer	0.000303	0.000382	CcSEcCtD
Glycopyrrolate—Confusional state—Capecitabine—breast cancer	0.000302	0.000382	CcSEcCtD
Glycopyrrolate—Tachycardia—Docetaxel—breast cancer	0.000302	0.000381	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Paclitaxel—breast cancer	0.000301	0.00038	CcSEcCtD
Glycopyrrolate—Skin disorder—Docetaxel—breast cancer	0.000301	0.00038	CcSEcCtD
Glycopyrrolate—Oedema—Capecitabine—breast cancer	0.0003	0.000378	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Paclitaxel—breast cancer	0.000299	0.000377	CcSEcCtD
Glycopyrrolate—Infection—Capecitabine—breast cancer	0.000298	0.000376	CcSEcCtD
Glycopyrrolate—Dizziness—Irinotecan—breast cancer	0.000296	0.000374	CcSEcCtD
Glycopyrrolate—Rhinitis—Epirubicin—breast cancer	0.000295	0.000372	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Doxorubicin—breast cancer	0.000295	0.000372	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Capecitabine—breast cancer	0.000294	0.000371	CcSEcCtD
Glycopyrrolate—Tachycardia—Capecitabine—breast cancer	0.000293	0.000369	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Epirubicin—breast cancer	0.000293	0.000369	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methotrexate—breast cancer	0.000292	0.000368	CcSEcCtD
Glycopyrrolate—Skin disorder—Capecitabine—breast cancer	0.000291	0.000368	CcSEcCtD
Glycopyrrolate—Sweating—Doxorubicin—breast cancer	0.000291	0.000367	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Epirubicin—breast cancer	0.00029	0.000366	CcSEcCtD
Glycopyrrolate—Urticaria—Paclitaxel—breast cancer	0.00029	0.000366	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Capecitabine—breast cancer	0.00029	0.000366	CcSEcCtD
Glycopyrrolate—Hypotension—Docetaxel—breast cancer	0.000289	0.000365	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Epirubicin—breast cancer	0.000289	0.000365	CcSEcCtD
Glycopyrrolate—Abdominal pain—Paclitaxel—breast cancer	0.000289	0.000365	CcSEcCtD
Glycopyrrolate—Body temperature increased—Paclitaxel—breast cancer	0.000289	0.000365	CcSEcCtD
Glycopyrrolate—Urethral disorder—Epirubicin—breast cancer	0.000288	0.000364	CcSEcCtD
Glycopyrrolate—Epistaxis—Doxorubicin—breast cancer	0.000286	0.000361	CcSEcCtD
Glycopyrrolate—Vomiting—Irinotecan—breast cancer	0.000285	0.000359	CcSEcCtD
Glycopyrrolate—Vomiting—Mitoxantrone—breast cancer	0.000285	0.000359	CcSEcCtD
Glycopyrrolate—Sinusitis—Doxorubicin—breast cancer	0.000284	0.000359	CcSEcCtD
Glycopyrrolate—Dizziness—Fluorouracil—breast cancer	0.000284	0.000358	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methotrexate—breast cancer	0.000283	0.000357	CcSEcCtD
Glycopyrrolate—Rash—Mitoxantrone—breast cancer	0.000283	0.000356	CcSEcCtD
Glycopyrrolate—Rash—Irinotecan—breast cancer	0.000283	0.000356	CcSEcCtD
Glycopyrrolate—Dermatitis—Irinotecan—breast cancer	0.000282	0.000356	CcSEcCtD
Glycopyrrolate—Dermatitis—Mitoxantrone—breast cancer	0.000282	0.000356	CcSEcCtD
Glycopyrrolate—Headache—Mitoxantrone—breast cancer	0.000281	0.000354	CcSEcCtD
Glycopyrrolate—Headache—Irinotecan—breast cancer	0.000281	0.000354	CcSEcCtD
Glycopyrrolate—Hypotension—Capecitabine—breast cancer	0.00028	0.000354	CcSEcCtD
Glycopyrrolate—Insomnia—Docetaxel—breast cancer	0.00028	0.000353	CcSEcCtD
Glycopyrrolate—Vomiting—Gemcitabine—breast cancer	0.000278	0.00035	CcSEcCtD
Glycopyrrolate—Somnolence—Docetaxel—breast cancer	0.000275	0.000347	CcSEcCtD
Glycopyrrolate—Mental disorder—Methotrexate—breast cancer	0.000275	0.000347	CcSEcCtD
Glycopyrrolate—Rash—Gemcitabine—breast cancer	0.000275	0.000347	CcSEcCtD
Glycopyrrolate—Dermatitis—Gemcitabine—breast cancer	0.000275	0.000347	CcSEcCtD
Glycopyrrolate—Malnutrition—Methotrexate—breast cancer	0.000274	0.000345	CcSEcCtD
Glycopyrrolate—Erythema—Methotrexate—breast cancer	0.000274	0.000345	CcSEcCtD
Glycopyrrolate—Headache—Gemcitabine—breast cancer	0.000273	0.000345	CcSEcCtD
Glycopyrrolate—Flushing—Epirubicin—breast cancer	0.000273	0.000344	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Epirubicin—breast cancer	0.000273	0.000344	CcSEcCtD
Glycopyrrolate—Vomiting—Fluorouracil—breast cancer	0.000273	0.000344	CcSEcCtD
Glycopyrrolate—Rhinitis—Doxorubicin—breast cancer	0.000273	0.000344	CcSEcCtD
Glycopyrrolate—Dyspepsia—Docetaxel—breast cancer	0.000273	0.000344	CcSEcCtD
Glycopyrrolate—Insomnia—Capecitabine—breast cancer	0.000271	0.000342	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Doxorubicin—breast cancer	0.000271	0.000342	CcSEcCtD
Glycopyrrolate—Rash—Fluorouracil—breast cancer	0.000271	0.000341	CcSEcCtD
Glycopyrrolate—Dermatitis—Fluorouracil—breast cancer	0.00027	0.000341	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Paclitaxel—breast cancer	0.000269	0.00034	CcSEcCtD
Glycopyrrolate—Headache—Fluorouracil—breast cancer	0.000269	0.000339	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Doxorubicin—breast cancer	0.000269	0.000339	CcSEcCtD
Glycopyrrolate—Dysgeusia—Methotrexate—breast cancer	0.000268	0.000338	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Docetaxel—breast cancer	0.000267	0.000337	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Doxorubicin—breast cancer	0.000267	0.000337	CcSEcCtD
Glycopyrrolate—Fatigue—Docetaxel—breast cancer	0.000267	0.000337	CcSEcCtD
Glycopyrrolate—Urethral disorder—Doxorubicin—breast cancer	0.000267	0.000337	CcSEcCtD
Glycopyrrolate—Nausea—Mitoxantrone—breast cancer	0.000266	0.000336	CcSEcCtD
Glycopyrrolate—Nausea—Irinotecan—breast cancer	0.000266	0.000336	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Epirubicin—breast cancer	0.000265	0.000334	CcSEcCtD
Glycopyrrolate—Pain—Docetaxel—breast cancer	0.000265	0.000334	CcSEcCtD
Glycopyrrolate—Constipation—Docetaxel—breast cancer	0.000265	0.000334	CcSEcCtD
Glycopyrrolate—Dyspepsia—Capecitabine—breast cancer	0.000264	0.000333	CcSEcCtD
Glycopyrrolate—Asthenia—Paclitaxel—breast cancer	0.000262	0.000331	CcSEcCtD
Glycopyrrolate—Nausea—Gemcitabine—breast cancer	0.000259	0.000327	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Capecitabine—breast cancer	0.000259	0.000327	CcSEcCtD
Glycopyrrolate—Fatigue—Capecitabine—breast cancer	0.000259	0.000326	CcSEcCtD
Glycopyrrolate—Pruritus—Paclitaxel—breast cancer	0.000259	0.000326	CcSEcCtD
Glycopyrrolate—Vision blurred—Methotrexate—breast cancer	0.000258	0.000325	CcSEcCtD
Glycopyrrolate—Mental disorder—Epirubicin—breast cancer	0.000258	0.000325	CcSEcCtD
Glycopyrrolate—Pain—Capecitabine—breast cancer	0.000256	0.000324	CcSEcCtD
Glycopyrrolate—Constipation—Capecitabine—breast cancer	0.000256	0.000324	CcSEcCtD
Glycopyrrolate—Malnutrition—Epirubicin—breast cancer	0.000256	0.000323	CcSEcCtD
Glycopyrrolate—Erythema—Epirubicin—breast cancer	0.000256	0.000323	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Docetaxel—breast cancer	0.000255	0.000322	CcSEcCtD
Glycopyrrolate—Nausea—Fluorouracil—breast cancer	0.000255	0.000322	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Docetaxel—breast cancer	0.000253	0.00032	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Doxorubicin—breast cancer	0.000253	0.000319	CcSEcCtD
Glycopyrrolate—Flushing—Doxorubicin—breast cancer	0.000253	0.000319	CcSEcCtD
Glycopyrrolate—Flatulence—Epirubicin—breast cancer	0.000252	0.000318	CcSEcCtD
Glycopyrrolate—Tension—Epirubicin—breast cancer	0.000251	0.000317	CcSEcCtD
Glycopyrrolate—Dysgeusia—Epirubicin—breast cancer	0.000251	0.000316	CcSEcCtD
Glycopyrrolate—Nervousness—Epirubicin—breast cancer	0.000249	0.000314	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Capecitabine—breast cancer	0.000247	0.000312	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Capecitabine—breast cancer	0.000245	0.000309	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Doxorubicin—breast cancer	0.000245	0.000309	CcSEcCtD
Glycopyrrolate—Body temperature increased—Docetaxel—breast cancer	0.000245	0.000309	CcSEcCtD
Glycopyrrolate—Abdominal pain—Docetaxel—breast cancer	0.000245	0.000309	CcSEcCtD
Glycopyrrolate—Dizziness—Paclitaxel—breast cancer	0.000242	0.000305	CcSEcCtD
Glycopyrrolate—Vision blurred—Epirubicin—breast cancer	0.000241	0.000304	CcSEcCtD
Glycopyrrolate—Mental disorder—Doxorubicin—breast cancer	0.000238	0.000301	CcSEcCtD
Glycopyrrolate—Urticaria—Capecitabine—breast cancer	0.000238	0.000301	CcSEcCtD
Glycopyrrolate—Abdominal pain—Capecitabine—breast cancer	0.000237	0.000299	CcSEcCtD
Glycopyrrolate—Body temperature increased—Capecitabine—breast cancer	0.000237	0.000299	CcSEcCtD
Glycopyrrolate—Convulsion—Methotrexate—breast cancer	0.000237	0.000299	CcSEcCtD
Glycopyrrolate—Malnutrition—Doxorubicin—breast cancer	0.000237	0.000299	CcSEcCtD
Glycopyrrolate—Erythema—Doxorubicin—breast cancer	0.000237	0.000299	CcSEcCtD
Glycopyrrolate—Agitation—Epirubicin—breast cancer	0.000235	0.000297	CcSEcCtD
Glycopyrrolate—Flatulence—Doxorubicin—breast cancer	0.000233	0.000295	CcSEcCtD
Glycopyrrolate—Tension—Doxorubicin—breast cancer	0.000232	0.000293	CcSEcCtD
Glycopyrrolate—Vomiting—Paclitaxel—breast cancer	0.000232	0.000293	CcSEcCtD
Glycopyrrolate—Dysgeusia—Doxorubicin—breast cancer	0.000232	0.000293	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000231	0.000292	CcSEcCtD
Glycopyrrolate—Rash—Paclitaxel—breast cancer	0.00023	0.000291	CcSEcCtD
Glycopyrrolate—Dermatitis—Paclitaxel—breast cancer	0.00023	0.00029	CcSEcCtD
Glycopyrrolate—Nervousness—Doxorubicin—breast cancer	0.00023	0.00029	CcSEcCtD
Glycopyrrolate—Headache—Paclitaxel—breast cancer	0.000229	0.000289	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Docetaxel—breast cancer	0.000228	0.000288	CcSEcCtD
Glycopyrrolate—Palpitations—Epirubicin—breast cancer	0.000226	0.000285	CcSEcCtD
Glycopyrrolate—Confusional state—Methotrexate—breast cancer	0.000225	0.000284	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methotrexate—breast cancer	0.000223	0.000282	CcSEcCtD
Glycopyrrolate—Vision blurred—Doxorubicin—breast cancer	0.000223	0.000282	CcSEcCtD
Glycopyrrolate—Asthenia—Docetaxel—breast cancer	0.000222	0.00028	CcSEcCtD
Glycopyrrolate—Convulsion—Epirubicin—breast cancer	0.000222	0.00028	CcSEcCtD
Glycopyrrolate—Infection—Methotrexate—breast cancer	0.000222	0.00028	CcSEcCtD
Glycopyrrolate—Hypertension—Epirubicin—breast cancer	0.000221	0.000279	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Capecitabine—breast cancer	0.000221	0.000279	CcSEcCtD
Glycopyrrolate—Pruritus—Docetaxel—breast cancer	0.000219	0.000277	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methotrexate—breast cancer	0.000219	0.000276	CcSEcCtD
Glycopyrrolate—Agitation—Doxorubicin—breast cancer	0.000218	0.000275	CcSEcCtD
Glycopyrrolate—Nausea—Paclitaxel—breast cancer	0.000217	0.000274	CcSEcCtD
Glycopyrrolate—Skin disorder—Methotrexate—breast cancer	0.000217	0.000274	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000216	0.000273	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methotrexate—breast cancer	0.000216	0.000272	CcSEcCtD
Glycopyrrolate—Asthenia—Capecitabine—breast cancer	0.000215	0.000271	CcSEcCtD
Glycopyrrolate—Dry mouth—Epirubicin—breast cancer	0.000213	0.000269	CcSEcCtD
Glycopyrrolate—Pruritus—Capecitabine—breast cancer	0.000212	0.000268	CcSEcCtD
Glycopyrrolate—Confusional state—Epirubicin—breast cancer	0.000211	0.000266	CcSEcCtD
Glycopyrrolate—Palpitations—Doxorubicin—breast cancer	0.000209	0.000264	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Epirubicin—breast cancer	0.000209	0.000264	CcSEcCtD
Glycopyrrolate—Oedema—Epirubicin—breast cancer	0.000209	0.000264	CcSEcCtD
Glycopyrrolate—Hypotension—Methotrexate—breast cancer	0.000209	0.000263	CcSEcCtD
Glycopyrrolate—Infection—Epirubicin—breast cancer	0.000208	0.000262	CcSEcCtD
Glycopyrrolate—Convulsion—Doxorubicin—breast cancer	0.000205	0.000259	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Epirubicin—breast cancer	0.000205	0.000259	CcSEcCtD
Glycopyrrolate—Dizziness—Docetaxel—breast cancer	0.000205	0.000258	CcSEcCtD
Glycopyrrolate—Hypertension—Doxorubicin—breast cancer	0.000205	0.000258	CcSEcCtD
Glycopyrrolate—Tachycardia—Epirubicin—breast cancer	0.000204	0.000257	CcSEcCtD
Glycopyrrolate—Skin disorder—Epirubicin—breast cancer	0.000203	0.000256	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Epirubicin—breast cancer	0.000202	0.000255	CcSEcCtD
Glycopyrrolate—Insomnia—Methotrexate—breast cancer	0.000202	0.000255	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.0002	0.000253	CcSEcCtD
Glycopyrrolate—Somnolence—Methotrexate—breast cancer	0.000198	0.00025	CcSEcCtD
Glycopyrrolate—Dizziness—Capecitabine—breast cancer	0.000198	0.00025	CcSEcCtD
Glycopyrrolate—Dry mouth—Doxorubicin—breast cancer	0.000197	0.000249	CcSEcCtD
Glycopyrrolate—Vomiting—Docetaxel—breast cancer	0.000197	0.000248	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methotrexate—breast cancer	0.000197	0.000248	CcSEcCtD
Glycopyrrolate—Rash—Docetaxel—breast cancer	0.000195	0.000246	CcSEcCtD
Glycopyrrolate—Hypotension—Epirubicin—breast cancer	0.000195	0.000246	CcSEcCtD
Glycopyrrolate—Dermatitis—Docetaxel—breast cancer	0.000195	0.000246	CcSEcCtD
Glycopyrrolate—Confusional state—Doxorubicin—breast cancer	0.000195	0.000246	CcSEcCtD
Glycopyrrolate—Headache—Docetaxel—breast cancer	0.000194	0.000245	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Doxorubicin—breast cancer	0.000193	0.000244	CcSEcCtD
Glycopyrrolate—Oedema—Doxorubicin—breast cancer	0.000193	0.000244	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Methotrexate—breast cancer	0.000193	0.000243	CcSEcCtD
Glycopyrrolate—Fatigue—Methotrexate—breast cancer	0.000192	0.000243	CcSEcCtD
Glycopyrrolate—Infection—Doxorubicin—breast cancer	0.000192	0.000242	CcSEcCtD
Glycopyrrolate—Pain—Methotrexate—breast cancer	0.000191	0.000241	CcSEcCtD
Glycopyrrolate—Vomiting—Capecitabine—breast cancer	0.000191	0.000241	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Doxorubicin—breast cancer	0.00019	0.000239	CcSEcCtD
Glycopyrrolate—Rash—Capecitabine—breast cancer	0.000189	0.000239	CcSEcCtD
Glycopyrrolate—Insomnia—Epirubicin—breast cancer	0.000189	0.000238	CcSEcCtD
Glycopyrrolate—Dermatitis—Capecitabine—breast cancer	0.000189	0.000238	CcSEcCtD
Glycopyrrolate—Tachycardia—Doxorubicin—breast cancer	0.000189	0.000238	CcSEcCtD
Glycopyrrolate—Headache—Capecitabine—breast cancer	0.000188	0.000237	CcSEcCtD
Glycopyrrolate—Skin disorder—Doxorubicin—breast cancer	0.000188	0.000237	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Doxorubicin—breast cancer	0.000187	0.000236	CcSEcCtD
Glycopyrrolate—Somnolence—Epirubicin—breast cancer	0.000186	0.000234	CcSEcCtD
Glycopyrrolate—Nausea—Docetaxel—breast cancer	0.000184	0.000232	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methotrexate—breast cancer	0.000184	0.000232	CcSEcCtD
Glycopyrrolate—Dyspepsia—Epirubicin—breast cancer	0.000184	0.000232	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methotrexate—breast cancer	0.000183	0.00023	CcSEcCtD
Glycopyrrolate—Hypotension—Doxorubicin—breast cancer	0.000181	0.000228	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Epirubicin—breast cancer	0.00018	0.000228	CcSEcCtD
Glycopyrrolate—Fatigue—Epirubicin—breast cancer	0.00018	0.000227	CcSEcCtD
Glycopyrrolate—Pain—Epirubicin—breast cancer	0.000179	0.000225	CcSEcCtD
Glycopyrrolate—Constipation—Epirubicin—breast cancer	0.000179	0.000225	CcSEcCtD
Glycopyrrolate—Nausea—Capecitabine—breast cancer	0.000178	0.000225	CcSEcCtD
Glycopyrrolate—Urticaria—Methotrexate—breast cancer	0.000177	0.000224	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methotrexate—breast cancer	0.000176	0.000223	CcSEcCtD
Glycopyrrolate—Body temperature increased—Methotrexate—breast cancer	0.000176	0.000223	CcSEcCtD
Glycopyrrolate—Insomnia—Doxorubicin—breast cancer	0.000175	0.000221	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Epirubicin—breast cancer	0.000172	0.000217	CcSEcCtD
Glycopyrrolate—Somnolence—Doxorubicin—breast cancer	0.000172	0.000217	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Epirubicin—breast cancer	0.000171	0.000216	CcSEcCtD
Glycopyrrolate—Dyspepsia—Doxorubicin—breast cancer	0.00017	0.000215	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000167	0.000211	CcSEcCtD
Glycopyrrolate—Fatigue—Doxorubicin—breast cancer	0.000167	0.00021	CcSEcCtD
Glycopyrrolate—Urticaria—Epirubicin—breast cancer	0.000166	0.000209	CcSEcCtD
Glycopyrrolate—Pain—Doxorubicin—breast cancer	0.000165	0.000209	CcSEcCtD
Glycopyrrolate—Constipation—Doxorubicin—breast cancer	0.000165	0.000209	CcSEcCtD
Glycopyrrolate—Body temperature increased—Epirubicin—breast cancer	0.000165	0.000208	CcSEcCtD
Glycopyrrolate—Abdominal pain—Epirubicin—breast cancer	0.000165	0.000208	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methotrexate—breast cancer	0.000164	0.000208	CcSEcCtD
Glycopyrrolate—Asthenia—Methotrexate—breast cancer	0.00016	0.000202	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Doxorubicin—breast cancer	0.000159	0.000201	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Doxorubicin—breast cancer	0.000158	0.000199	CcSEcCtD
Glycopyrrolate—Pruritus—Methotrexate—breast cancer	0.000158	0.000199	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Epirubicin—breast cancer	0.000154	0.000194	CcSEcCtD
Glycopyrrolate—Urticaria—Doxorubicin—breast cancer	0.000154	0.000194	CcSEcCtD
Glycopyrrolate—Abdominal pain—Doxorubicin—breast cancer	0.000153	0.000193	CcSEcCtD
Glycopyrrolate—Body temperature increased—Doxorubicin—breast cancer	0.000153	0.000193	CcSEcCtD
Glycopyrrolate—Asthenia—Epirubicin—breast cancer	0.00015	0.000189	CcSEcCtD
Glycopyrrolate—Pruritus—Epirubicin—breast cancer	0.000148	0.000187	CcSEcCtD
Glycopyrrolate—Dizziness—Methotrexate—breast cancer	0.000148	0.000186	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Doxorubicin—breast cancer	0.000142	0.00018	CcSEcCtD
Glycopyrrolate—Vomiting—Methotrexate—breast cancer	0.000142	0.000179	CcSEcCtD
Glycopyrrolate—Rash—Methotrexate—breast cancer	0.000141	0.000178	CcSEcCtD
Glycopyrrolate—Dermatitis—Methotrexate—breast cancer	0.000141	0.000177	CcSEcCtD
Glycopyrrolate—Headache—Methotrexate—breast cancer	0.00014	0.000176	CcSEcCtD
Glycopyrrolate—Asthenia—Doxorubicin—breast cancer	0.000139	0.000175	CcSEcCtD
Glycopyrrolate—Dizziness—Epirubicin—breast cancer	0.000138	0.000174	CcSEcCtD
Glycopyrrolate—Pruritus—Doxorubicin—breast cancer	0.000137	0.000173	CcSEcCtD
Glycopyrrolate—Vomiting—Epirubicin—breast cancer	0.000133	0.000168	CcSEcCtD
Glycopyrrolate—Nausea—Methotrexate—breast cancer	0.000133	0.000167	CcSEcCtD
Glycopyrrolate—Rash—Epirubicin—breast cancer	0.000132	0.000166	CcSEcCtD
Glycopyrrolate—Dermatitis—Epirubicin—breast cancer	0.000132	0.000166	CcSEcCtD
Glycopyrrolate—Headache—Epirubicin—breast cancer	0.000131	0.000165	CcSEcCtD
Glycopyrrolate—Dizziness—Doxorubicin—breast cancer	0.000128	0.000161	CcSEcCtD
Glycopyrrolate—Nausea—Epirubicin—breast cancer	0.000124	0.000157	CcSEcCtD
Glycopyrrolate—Vomiting—Doxorubicin—breast cancer	0.000123	0.000155	CcSEcCtD
Glycopyrrolate—Rash—Doxorubicin—breast cancer	0.000122	0.000154	CcSEcCtD
Glycopyrrolate—Dermatitis—Doxorubicin—breast cancer	0.000122	0.000154	CcSEcCtD
Glycopyrrolate—Headache—Doxorubicin—breast cancer	0.000121	0.000153	CcSEcCtD
Glycopyrrolate—Nausea—Doxorubicin—breast cancer	0.000115	0.000145	CcSEcCtD
Glycopyrrolate—CHRM4—Signaling Pathways—RAF1—breast cancer	2.34e-05	0.000116	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—RELA—breast cancer	2.33e-05	0.000116	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FGFR1—breast cancer	2.31e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—ERBB2—breast cancer	2.31e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FGFR1—breast cancer	2.31e-05	0.000115	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FGFR1—breast cancer	2.28e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MTOR—breast cancer	2.28e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CB—breast cancer	2.28e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—HIF1A—breast cancer	2.28e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—HIF1A—breast cancer	2.27e-05	0.000113	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—PIK3CA—breast cancer	2.25e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—HIF1A—breast cancer	2.25e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MDM2—breast cancer	2.24e-05	0.000112	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—RAF1—breast cancer	2.24e-05	0.000111	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—RELA—breast cancer	2.23e-05	0.000111	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—LEP—breast cancer	2.22e-05	0.000111	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—LEP—breast cancer	2.22e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—ERBB2—breast cancer	2.21e-05	0.00011	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CAV1—breast cancer	2.2e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CAV1—breast cancer	2.2e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—LEP—breast cancer	2.2e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CXCL8—breast cancer	2.19e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MTOR—breast cancer	2.18e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CB—breast cancer	2.18e-05	0.000109	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KDR—breast cancer	2.18e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—HRAS—breast cancer	2.18e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CAV1—breast cancer	2.17e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KDR—breast cancer	2.17e-05	0.000108	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KDR—breast cancer	2.15e-05	0.000107	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CDKN1B—breast cancer	2.14e-05	0.000106	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ESR1—breast cancer	2.12e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM4—GPCR downstream signaling—AKT1—breast cancer	2.12e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ESR1—breast cancer	2.12e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CD—breast cancer	2.1e-05	0.000105	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CXCL8—breast cancer	2.1e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CASP3—breast cancer	2.1e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FN1—breast cancer	2.1e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ESR1—breast cancer	2.1e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL2—breast cancer	2.09e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FN1—breast cancer	2.09e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—HRAS—breast cancer	2.09e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—IL6—breast cancer	2.08e-05	0.000104	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—ALB—breast cancer	2.08e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NFKBIA—breast cancer	2.07e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FN1—breast cancer	2.07e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NFKBIA—breast cancer	2.07e-05	0.000103	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NOTCH1—breast cancer	2.05e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CDKN1B—breast cancer	2.05e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NOTCH1—breast cancer	2.05e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NFKBIA—breast cancer	2.05e-05	0.000102	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CCND1—breast cancer	2.04e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—JUN—breast cancer	2.04e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—AKT1—breast cancer	2.03e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NOTCH1—breast cancer	2.03e-05	0.000101	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CTNNB1—breast cancer	2.02e-05	0.0001	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CASP3—breast cancer	2.01e-05	9.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KIT—breast cancer	2.01e-05	9.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CG—breast cancer	2.01e-05	9.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—APC—breast cancer	2.01e-05	9.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL2—breast cancer	2.01e-05	9.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—APC—breast cancer	2e-05	9.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CG—breast cancer	2e-05	9.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KIT—breast cancer	2e-05	9.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—IL6—breast cancer	2e-05	9.92e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—NOS3—breast cancer	1.99e-05	9.87e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EGF—breast cancer	1.98e-05	9.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MMP9—breast cancer	1.98e-05	9.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KIT—breast cancer	1.98e-05	9.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CG—breast cancer	1.98e-05	9.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—APC—breast cancer	1.98e-05	9.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EGF—breast cancer	1.98e-05	9.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CDKN1A—breast cancer	1.98e-05	9.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PTEN—breast cancer	1.97e-05	9.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EGF—breast cancer	1.96e-05	9.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CCND1—breast cancer	1.96e-05	9.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—JUN—breast cancer	1.95e-05	9.7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CTNNB1—breast cancer	1.94e-05	9.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MAPK8—breast cancer	1.93e-05	9.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—AKT1—breast cancer	1.92e-05	9.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—MAPK3—breast cancer	1.92e-05	9.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—MAPK3—breast cancer	1.92e-05	9.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MMP9—breast cancer	1.9e-05	9.43e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—MAPK3—breast cancer	1.9e-05	9.43e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CDKN1A—breast cancer	1.89e-05	9.4e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PTEN—breast cancer	1.89e-05	9.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—BRAF—breast cancer	1.89e-05	9.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—BRAF—breast cancer	1.88e-05	9.34e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—BRAF—breast cancer	1.86e-05	9.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAPK8—breast cancer	1.85e-05	9.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—AKT1—breast cancer	1.84e-05	9.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IGF1—breast cancer	1.84e-05	9.13e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AKT2—breast cancer	1.84e-05	9.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CB—breast cancer	1.83e-05	9.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IGF1—breast cancer	1.83e-05	9.1e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AKT2—breast cancer	1.83e-05	9.1e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—EGFR—breast cancer	1.83e-05	9.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—SRC—breast cancer	1.83e-05	9.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—EGFR—breast cancer	1.82e-05	9.06e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTGS2—breast cancer	1.82e-05	9.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IGF1—breast cancer	1.81e-05	9.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AKT2—breast cancer	1.81e-05	9.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—EGFR—breast cancer	1.8e-05	8.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—VEGFA—breast cancer	1.78e-05	8.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CD—breast cancer	1.76e-05	8.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—STAT3—breast cancer	1.76e-05	8.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CD—breast cancer	1.76e-05	8.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—SRC—breast cancer	1.75e-05	8.7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	1.75e-05	8.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SERPINE1—breast cancer	1.74e-05	8.67e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	1.74e-05	8.66e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CD—breast cancer	1.74e-05	8.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SERPINE1—breast cancer	1.74e-05	8.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—KRAS—breast cancer	1.73e-05	8.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	1.73e-05	8.57e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SERPINE1—breast cancer	1.72e-05	8.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—KRAS—breast cancer	1.72e-05	8.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—KRAS—breast cancer	1.71e-05	8.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—VEGFA—breast cancer	1.7e-05	8.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—STAT3—breast cancer	1.69e-05	8.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MAPK3—breast cancer	1.68e-05	8.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NOS3—breast cancer	1.67e-05	8.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NOS3—breast cancer	1.66e-05	8.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NOS3—breast cancer	1.64e-05	8.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MYC—breast cancer	1.64e-05	8.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TGFB1—breast cancer	1.63e-05	8.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAPK3—breast cancer	1.61e-05	8.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—EGFR—breast cancer	1.6e-05	7.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	1.59e-05	7.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTEN—breast cancer	1.58e-05	7.87e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	1.58e-05	7.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MDM2—breast cancer	1.58e-05	7.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MDM2—breast cancer	1.58e-05	7.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—RAF1—breast cancer	1.58e-05	7.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—RAF1—breast cancer	1.57e-05	7.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MYC—breast cancer	1.57e-05	7.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—RELA—breast cancer	1.57e-05	7.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	1.57e-05	7.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TGFB1—breast cancer	1.56e-05	7.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—RELA—breast cancer	1.56e-05	7.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MDM2—breast cancer	1.56e-05	7.75e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ERBB2—breast cancer	1.56e-05	7.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—RAF1—breast cancer	1.55e-05	7.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ERBB2—breast cancer	1.55e-05	7.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—RELA—breast cancer	1.55e-05	7.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ERBB2—breast cancer	1.54e-05	7.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CB—breast cancer	1.54e-05	7.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MTOR—breast cancer	1.54e-05	7.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—EGFR—breast cancer	1.53e-05	7.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CB—breast cancer	1.53e-05	7.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MTOR—breast cancer	1.53e-05	7.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CB—breast cancer	1.52e-05	7.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MTOR—breast cancer	1.52e-05	7.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—KRAS—breast cancer	1.51e-05	7.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CXCL8—breast cancer	1.48e-05	7.34e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CXCL8—breast cancer	1.47e-05	7.32e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—HRAS—breast cancer	1.47e-05	7.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—HRAS—breast cancer	1.46e-05	7.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CXCL8—breast cancer	1.46e-05	7.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—HRAS—breast cancer	1.45e-05	7.2e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—KRAS—breast cancer	1.45e-05	7.2e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CDKN1B—breast cancer	1.44e-05	7.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CDKN1B—breast cancer	1.44e-05	7.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—AKT1—breast cancer	1.43e-05	7.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CDKN1B—breast cancer	1.42e-05	7.08e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—AKT1—breast cancer	1.42e-05	7.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CASP3—breast cancer	1.41e-05	7.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL2—breast cancer	1.41e-05	7.02e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CASP3—breast cancer	1.41e-05	7.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—AKT1—breast cancer	1.41e-05	7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL2—breast cancer	1.41e-05	7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—IL6—breast cancer	1.41e-05	6.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—IL6—breast cancer	1.4e-05	6.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CASP3—breast cancer	1.4e-05	6.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL2—breast cancer	1.39e-05	6.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CA—breast cancer	1.39e-05	6.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—IL6—breast cancer	1.39e-05	6.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CCND1—breast cancer	1.38e-05	6.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—JUN—breast cancer	1.37e-05	6.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CCND1—breast cancer	1.37e-05	6.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—JUN—breast cancer	1.37e-05	6.81e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CTNNB1—breast cancer	1.36e-05	6.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CCND1—breast cancer	1.36e-05	6.75e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CTNNB1—breast cancer	1.36e-05	6.75e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—JUN—breast cancer	1.36e-05	6.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CTNNB1—breast cancer	1.35e-05	6.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TP53—breast cancer	1.34e-05	6.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MMP9—breast cancer	1.34e-05	6.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MMP9—breast cancer	1.33e-05	6.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CDKN1A—breast cancer	1.33e-05	6.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CA—breast cancer	1.33e-05	6.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PTEN—breast cancer	1.33e-05	6.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CDKN1A—breast cancer	1.33e-05	6.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PTEN—breast cancer	1.32e-05	6.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MMP9—breast cancer	1.32e-05	6.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CDKN1A—breast cancer	1.31e-05	6.53e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PTEN—breast cancer	1.31e-05	6.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAPK8—breast cancer	1.3e-05	6.46e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—AKT1—breast cancer	1.3e-05	6.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAPK8—breast cancer	1.3e-05	6.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—AKT1—breast cancer	1.29e-05	6.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TP53—breast cancer	1.29e-05	6.4e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—HRAS—breast cancer	1.29e-05	6.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAPK8—breast cancer	1.28e-05	6.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—AKT1—breast cancer	1.28e-05	6.36e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SRC—breast cancer	1.23e-05	6.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—HRAS—breast cancer	1.23e-05	6.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL6—breast cancer	1.23e-05	6.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SRC—breast cancer	1.23e-05	6.1e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SRC—breast cancer	1.22e-05	6.04e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—VEGFA—breast cancer	1.2e-05	5.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—VEGFA—breast cancer	1.2e-05	5.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—STAT3—breast cancer	1.19e-05	5.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—VEGFA—breast cancer	1.18e-05	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—STAT3—breast cancer	1.18e-05	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL6—breast cancer	1.18e-05	5.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—STAT3—breast cancer	1.17e-05	5.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—AKT1—breast cancer	1.14e-05	5.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAPK3—breast cancer	1.14e-05	5.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAPK3—breast cancer	1.13e-05	5.62e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAPK3—breast cancer	1.12e-05	5.57e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CA—breast cancer	1.12e-05	5.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MYC—breast cancer	1.1e-05	5.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TGFB1—breast cancer	1.1e-05	5.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MYC—breast cancer	1.1e-05	5.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TGFB1—breast cancer	1.1e-05	5.46e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MYC—breast cancer	1.09e-05	5.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—AKT1—breast cancer	1.09e-05	5.4e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TGFB1—breast cancer	1.09e-05	5.4e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—EGFR—breast cancer	1.08e-05	5.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—EGFR—breast cancer	1.08e-05	5.35e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—EGFR—breast cancer	1.07e-05	5.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—KRAS—breast cancer	1.02e-05	5.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—KRAS—breast cancer	1.02e-05	5.05e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—KRAS—breast cancer	1.01e-05	5.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CA—breast cancer	9.37e-06	4.66e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CA—breast cancer	9.34e-06	4.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CA—breast cancer	9.25e-06	4.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—AKT1—breast cancer	9.13e-06	4.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TP53—breast cancer	9.07e-06	4.51e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TP53—breast cancer	9.04e-06	4.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TP53—breast cancer	8.95e-06	4.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—HRAS—breast cancer	8.67e-06	4.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—HRAS—breast cancer	8.65e-06	4.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—HRAS—breast cancer	8.56e-06	4.25e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL6—breast cancer	8.3e-06	4.12e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL6—breast cancer	8.27e-06	4.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL6—breast cancer	8.19e-06	4.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AKT1—breast cancer	7.66e-06	3.81e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AKT1—breast cancer	7.63e-06	3.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AKT1—breast cancer	7.56e-06	3.76e-05	CbGpPWpGaD
